Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Greensboro, NC

    Search
    Greensboro, NC
    Show Map
    Map View
    Greensboro, NC
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      205 Clinical Paid Trials near Greensboro, NC

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Salt Reduction Diet for High Blood Pressure

      Winston-Salem, North Carolina
      This trial is studying young adults who were born prematurely to understand how salt affects their blood pressure. Researchers will see if stopping the body from making uric acid can help lower their blood pressure and improve heart health. The goal is to find better ways to prevent and treat heart disease in this high-risk group. Uric acid has been suspected to be a risk factor for high blood pressure since the 1870s, and lowering uric acid has shown potential in reducing blood pressure in individuals with high blood pressure.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:22 - 33

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Cancer, Kidney, Heart, Liver, Others
      Must Not Be Taking:Antihypertensives

      120 Participants Needed

      Bioengineered Penile Tissue for Penile Damage

      Winston-Salem, North Carolina
      The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. Autologous endothelial and smooth muscle cells obtained from enrolled subjects' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa/albuginea constructs for repair of damaged penile tissues.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1
      Age:18 - 60
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Diabetes, Cardiac Disorders, Pulmonary Disorders, Alcohol/drug Abuse, Others
      Must Not Be Taking:Immunosuppressants

      10 Participants Needed

      Engineered Urethral Tissue for Urethral Stricture

      Winston-Salem, North Carolina
      This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males. The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:21 - 75
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Diabetes, HIV, Hepatitis, Others
      Must Not Be Taking:Alpha Blockers, Anticoagulants, Immunosuppressants, Others

      10 Participants Needed

      Navtemadlin for Brain Cancer

      Winston-Salem, North Carolina
      This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Active Infection, Cardiac Arrhythmia, Others
      Must Be Taking:Corticosteroids

      86 Participants Needed

      T Lymphocyte Therapy for Lymphoma

      Winston-Salem, North Carolina
      The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been sufficient to cure most patients. This study is designed to combine both T cells and antibodies to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) administration. In previous studies, it has been shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying the patient's genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD30. This antibody floats around in the blood and can detect and stick to cancer cells called lymphoma cells because they have a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymphoma cells is attached to the T cells instead of the entire antibody. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. The purpose of this research study is to determine a safe dose of the ATLCAR.CD30 cells that can be given to subjects after undergoing an autologous transplant. This is the first step in determining whether giving ATLCAR.CD30 cells to others with lymphoma in the future will help them. The researchers also want to find out what side effects patients will have after they receive the ATLCAR.CD30 cells post-transplant. This study will also look at other effects of ATLCAR.CD30 cells, including their effect on your cancer and how long they will survive in your body.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:3+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, HBV, HCV, Others
      Must Not Be Taking:Anti-CD30 Antibodies, Corticosteroids

      18 Participants Needed

      SGN-MesoC2 for Solid Tumors

      Winston-Salem, North Carolina
      This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:HIV, Uncontrolled Hypertension, Diabetes, Others
      Must Not Be Taking:Anticancer Drugs, Radiotherapy

      365 Participants Needed

      ABBV-383 for Multiple Myeloma

      Winston-Salem, North Carolina
      Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 25 sites across the world In Arm A participants will receive one of two doses of ABBV-383 as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:None
      Must Not Be Taking:BCMAxCD3 Bispecific

      55 Participants Needed

      AMG 355 + Pembrolizumab for Advanced Solid Tumors

      Winston-Salem, North Carolina
      The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Autoimmune Disease, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants

      535 Participants Needed

      INCA033989 for Myeloproliferative Disorder

      Winston-Salem, North Carolina
      This trial is testing a new drug called INCA033989 in patients with a type of blood cancer. The goal is to find the safest and most effective dose by checking for side effects and how well the drug works.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Hematological Malignancy, Major Bleeding, Cardiac Disease, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Endocrine Therapy, Others

      230 Participants Needed

      Combination Therapy for B-Cell Lymphoma

      Winston-Salem, North Carolina
      This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab, linked to a toxic agent called vedotin, attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Giving mosunetuzumab with polatuzumab vedotin and lenalidomide may work better in treating patients with relapsed/refractory DLBCL.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Plasmablastic Lymphoma, Active Infection, Pregnancy, Others
      Must Not Be Taking:Investigational Agents

      30 Participants Needed

      SNDX-5613 + Chemotherapy for Acute Myeloid Leukemia

      Winston-Salem, North Carolina
      This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding SNDX-5613 to the standard chemotherapy treatment may be able to shrink or stabilize the cancer for longer than the standard chemotherapy treatment alone.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, CNS Involvement, Others
      Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers

      28 Participants Needed

      ABBV-383 for Multiple Myeloma

      Winston-Salem, North Carolina
      This trial tests ABBV-383, a new drug for adults with multiple myeloma that has come back or not responded to other treatments. The drug is given through an IV regularly. The study will monitor the drug's effects and any side effects over several years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Rapidly Progressing Disease, Others
      Must Be Taking:Proteasome Inhibitors, IMiDs, Anti-CD38

      180 Participants Needed

      Adherence Strategies + Otezla for Psoriasis

      Winston-Salem, North Carolina
      Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.
      No Placebo Group

      Trial Details

      Trial Status:Withdrawn
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Under 18, Pregnant, Others
      Must Be Taking:Otezla

      Oral OKN-007 for Brain Tumor

      Winston-Salem, North Carolina
      This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Prior Malignancy, Cardiac Disease, Others
      Must Not Be Taking:Bevacizumab, Chemotherapeutics

      16 Participants Needed

      Fat Cell Injection for Knee Osteoarthritis

      Winston-Salem, North Carolina
      This is a prospective, non-randomized, interventional, dual site, before-after clinical trial to determine feasibility and safety of a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF) for the treatment of knee Post Traumatic Osteoarthritis (PTOA).
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Early Phase 1
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:Gout, Rheumatoid Arthritis, Lupus, Others
      Must Not Be Taking:Oral Steroids, Immunosuppressants

      10 Participants Needed

      JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia

      Winston-Salem, North Carolina
      This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, Down Syndrome, Others

      200 Participants Needed

      Nirmatrelvir + Ritonavir for COVID-19 in Pregnancy

      Winston-Salem, North Carolina
      The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects can be tolerated for treatment of pregnant women with mild or moderate COVID-19 compared to non-pregnant women with mild or moderate COVID-19. This study is seeking participants who: * are expecting a healthy baby and are in their second or third trimester pregnancy and have mild or moderate COVID-19 * are not pregnant and have mild or moderate COVID-19. All participants in this study will take Paxlovid by mouth every 12 hours for 5 days. We will study the experiences of people receiving the study medicine. This will help us decide if the study medicine is safe. All participants will take part in this study for at least 34 days; pregnant participants will take part until their delivery, so that the study duration may be up to 6 months, depending on their delivery date. During this time, participants will have 7to 8 visits and, if pregnant, a visit at delivery. Around 2 to 3 visits and the delivery visit will be done in person (at the clinic or at the participant's home). The other 5 visits may be done over the phone, unless in-person visit is necessary as decided by the doctor. Blood samples will be collected on the first 4 to 5 study visits (and at other study visits, if necessary).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 50
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Hospitalization, Kidney Impairment, Others
      Must Not Be Taking:CYP3A4 Drugs, Antivirals

      25 Participants Needed

      ASP2138 for Digestive System Cancers

      Winston-Salem, North Carolina
      This trial is testing a new drug called ASP2138 for adults with advanced stomach, gastroesophageal junction, or pancreatic cancer. ASP2138 helps the immune system target and attack cancer cells. The study aims to find a safe and effective dose and monitor any side effects. Participants will receive the drug through an IV or injection and will be closely monitored throughout the study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, CNS Metastases, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      398 Participants Needed

      Tazemetostat + Topotecan + Pembrolizumab for Small Cell Lung Cancer

      Winston-Salem, North Carolina
      This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Autoimmune Disease, Pneumonitis, Uncontrolled Illness, Others
      Must Not Be Taking:Immunosuppressants, Steroids

      60 Participants Needed

      Talquetamab/Teclistamab + PD-1 Inhibitor for Multiple Myeloma

      Winston-Salem, North Carolina
      The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Plasma Cell Leukemia, Waldenstrom's, POEMS, Others
      Must Not Be Taking:PD-1 Inhibitors

      74 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Trial

      ABBV-453 for Multiple Myeloma

      Winston Salem, North Carolina
      This trial tests ABBV-453, a new drug for adults with multiple myeloma that has come back or didn't respond to other treatments. The drug aims to stop cancer cell growth and is tested alone or with other medications to find the best treatment combination.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:ECG Abnormalities, Others
      Must Not Be Taking:Venetoclax, BCL-2 Inhibitors

      34 Participants Needed

      Linvoseltamab Combo for Multiple Myeloma

      Winston-Salem, North Carolina
      This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma * What side effects may happen from taking linvoseltamab together with another cancer treatment * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Plasma Cell Leukemia, Brain Lesions, Others
      Must Not Be Taking:BCMA Immunotherapies, Anti-PD-1, Others

      317 Participants Needed

      Abemaciclib + Olaparib for Recurrent Ovarian Cancer

      Winston-Salem, North Carolina
      This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiac Conditions, MDS/AML, Others
      Must Not Be Taking:CYP3A Inhibitors

      42 Participants Needed

      Intratumoral Microdosing for Cancer

      Winston-Salem, North Carolina
      This trial uses a device to inject small amounts of cancer drugs directly into tumors of patients undergoing surgery. The device marks where each drug is injected, allowing researchers to see how different parts of the tumor respond. This helps test cancer drugs early without causing widespread side effects. The device has been shown to induce strong, easily tracked, drug-specific responses in tumors while avoiding toxicity, setting the stage for its application in clinical trials.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Uncontrolled Illness, Others

      15 Participants Needed

      CLBR001 CAR-T for Non-Hodgkin's Lymphoma

      Winston-Salem, North Carolina
      This trial involves monitoring patients who received a special cancer treatment using their own modified immune cells. These patients are followed for an extended period to check for safety and effectiveness. The treatment works by reprogramming the patient's immune cells to better fight cancer and has shown promising results.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 1

      36 Participants Needed

      AMG 509 for Prostate Cancer

      Winston-Salem, North Carolina
      This trial is testing a new drug called AMG 509 in adults to see if it is safe and to find the best dose. The study will monitor how people react to different doses.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Small Cell Carcinoma, CNS Metastases, Others
      Must Be Taking:GnRH Agonist/antagonist

      479 Participants Needed

      Daratumumab + T Cell Redirecting Antibodies for Multiple Myeloma

      Winston-Salem, North Carolina
      The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active CNS Involvement, Hepatitis B, Others
      Must Not Be Taking:Anti-CD38 Therapy

      290 Participants Needed

      Gemcitabine + Docetaxel + Radiation for Soft Tissue Sarcoma

      Winston-Salem, North Carolina
      The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Nursing, Amputation, Others
      Must Not Be Taking:Hormonal Therapy, Biologic, Chemotherapy

      27 Participants Needed

      Copanlisib + Usual Treatment for Advanced Breast Cancer

      Winston-Salem, North Carolina
      This phase I trial studies the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2 negative breast cancer that has spread from where it first started (breast) to other places in the body (metastatic). Some breast cancer cells have receptors for the hormones estrogen or progesterone. These cells are hormone receptor positive and they need estrogen or progesterone to grow. This can affect how the cancer is treated. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Abemaciclib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding copanlisib to the usual therapy of fulvestrant and abemaciclib may work better than giving fulvestrant and abemaciclib alone in treating patients with breast cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastasis, Autoimmune Disease, Others
      Must Be Taking:Fulvestrant, Abemaciclib

      24 Participants Needed

      Chemotherapy Tolerance in Elderly Patients with Breast Cancer

      Winston-Salem, North Carolina
      This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:70+

      Key Eligibility Criteria

      Disqualifiers:Prior Chemotherapy, Allergic Reactions, Others
      Must Not Be Taking:Investigational Agents

      41 Participants Needed

      1...4567

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Greensboro, NC pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Greensboro, NC work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Greensboro, NC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Greensboro, NC is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Greensboro, NC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Greensboro, NC?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Greensboro, NC?

      Most recently, we added Peer Navigator Training for HIV Prevention in Hispanic/Latino Men, Platelet-rich Plasma Therapy for Hair Loss and Bioengineered Penile Tissue for Penile Damage to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in North Carolina

      Anxiety Clinical Trials in North Carolina

      Schizophrenia Clinical Trials in North Carolina

      ADHD Clinical Trials in North Carolina

      Bipolar Disorder Clinical Trials in North Carolina

      Multiple Sclerosis Clinical Trials in North Carolina

      Autism Clinical Trials in North Carolina

      Treatment Resistant Depression Clinical Trials in North Carolina

      Borderline Personality Disorder Clinical Trials in North Carolina

      Social Anxiety Disorder Clinical Trials in North Carolina

      Parkinson's Disease Clinical Trials in North Carolina

      Alzheimer's Disease Clinical Trials in North Carolina

      By Location

      Clinical Trials near Durham, NC

      Clinical Trials near Winston-Salem, NC

      Clinical Trials near Charlotte, NC

      Clinical Trials near Chapel Hill, NC

      Clinical Trials near Raleigh, NC

      Clinical Trials near Asheville, NC

      Clinical Trials near Greensboro, NC

      Clinical Trials near Greenville, NC

      Clinical Trials near Wilmington, NC

      Clinical Trials near High Point, NC

      Clinical Trials near Goldsboro, NC

      Clinical Trials near Hickory, NC

      Other People Viewed

      By Subject

      204 Clinical Trials near Greensboro, NC

      20 Depression Trials near High Point, NC

      17 Alzheimer's Disease Trials near High Point, NC

      42 Alzheimer's Disease Trials near Raleigh, NC

      23 Weight Loss Trials near Raleigh, NC

      174 Clinical Trials near Cary, NC

      Top Clinical Trials near Clemmons, NC

      Top Clinical Trials near Concord, NC

      Top Clinical Trials near Butner, NC

      Top Clinical Trials near Asheboro, NC

      Top Clinical Trials near Charlotte, NC

      Top Clinical Trials near Elizabeth City, NC

      By Trial

      JessieHug for Sudden Infant Death Syndrome

      Stem Cell Transplant vs Best Available Therapy for Multiple Sclerosis

      DF-003 for ROSAH Syndrome

      Ablation and LAA Exclusion Systems for Atrial Fibrillation

      CRISPR-Cas9 Modified Stem Cells for Sickle Cell Disease

      ATM-AVI for Bacterial Infections in Infants

      Selumetinib Granules for Neurofibromatosis

      Bowel Preparation with CLENPIQ vs. MIRALAX for Colon Cleansing

      Cancer Vaccine for Lung Cancer

      Modified Cochlear Implant for Hearing Loss

      Cenobamate for Seizures

      IV Lidocaine for Hernia Repair

      Related Searches

      Top Clinical Trials near Ohio

      Top Clinical Trials near Greensboro, NC

      Resistance Exercise for Muscle Insulin Sensitivity

      Split-Dose R-CHOP for Lymphoma

      Marketing Strategies for Prediabetes

      Sprint Interval Training for Spinal Cord Injury

      Imaginal Exposure for Hoarding Disorder

      Imagined Muscle Contractions for Healthy Individuals

      Nutritional Supplementation for Bruising

      NEXUS Stent Graft for Aortic Disease

      AI-Generated Nutritional Messaging for Colorectal Cancer Survivors

      NEXI-001 + Decitabine for AML or MDS